Skip to content

Combination of Artificial Intelligence and Mucosal Exposure Device to Enhance Colorectal Neoplasia Detection

Combination of Artificial Intelligence (ENDOAID) and Mucosal Exposure Device (ENDOCUFF) to Enhance Colorectal Neoplasia Detection: a Randomized Controlled Trial

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05414448
Acronym
AIDEN
Enrollment
1726
Registered
2022-06-10
Start date
2023-03-07
Completion date
2025-12-31
Last updated
2024-05-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Adenoma, Colorectal Cancer, Colorectal Neoplasms

Brief summary

The investigators hypothesize that the combined use of CADe system (ENDOAID) and mucosal exposure device (Endocuff Vision®) would improve the adenoma detection rate when compared to CADe system alone.

Detailed description

High polyp miss rates were reported in standard colonoscopies. As a result, a significant proportion of interval CRC was attributed to the missed lesions during index colonoscopy. Risk factors of missed lesions included proximal location, serrate or flat morphology, poor bowel preparation, short withdrawal time and endoscopist experience. To overcome this pitfall, various methods were developed to improve adenoma detection rate (ADR), including distal attachment devices. Among the mucosal exposure devices, Endocuff Vision® was shown to be superior than conventional colonoscopies. Recently, artificial intelligence and automatic computer-aided polyp detection (CADe) systems have developed rapidly and revolutionized the medical field. Nevertheless, there was a potential limitation of 'blind spot' if the endoscopist failed to expose the colonic mucosa adequately leading to missed lesions. To date, no available data or ongoing clinical trial was reported regarding the combined use of CADe and mucosal exposure devices. It may enhance the performance of CADe and provide a novel definitive solution to this unaddressed yet important clinical problem. In this prospective parallel randomized controlled trial, we aim to evaluate the impact of combined use of a new CADe system (ENDOAID) and mucosal exposure device (Endocuff Vision®) on colorectal neoplasia detection.

Interventions

DEVICEENDOCUFF

ENDOCUFF mucousal exposure device will be used during withdrawal process of the colonoscopy.

Sponsors

University Hospital Augsburg
CollaboratorOTHER
Changi General Hospital
CollaboratorOTHER
Chinese University of Hong Kong
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
DIAGNOSTIC
Masking
DOUBLE (Subject, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
45 Years to 85 Years
Healthy volunteers
Yes

Inclusion criteria

1. Aged 45-85 years old; 2. They require elective colonoscopy for colorectal cancer screening, polyp surveillance, or investigation of symptoms such as anemia or altered bowel habit; 3. Written informed consent obtained.

Exclusion criteria

1. Contraindication to colonoscopy (e.g. intestinal obstruction or perforation) 2. Contraindication or conditions precluding polyp resection (e.g. active gastrointestinal bleeding, uninterrupted anticoagulation or dual antiplatelets) 3. Staged procedure for polypectomy or biopsy of known unresected lesions 4. Previous surgical resection of colon 5. Personal history of colorectal cancer 6. Personal history of familial polyposis syndrome 7. Personal history of inflammatory bowel disease 8. Advanced comorbid conditions (defined as American Society of Anesthesiologists grade 4 or above) 9. Pregnancy 10. Unable to obtain informed consent

Design outcomes

Primary

MeasureTime frameDescription
ADRDuring the colonoscopyadenoma detection rate

Secondary

MeasureTime frameDescription
ADR for adenomas of different colonic segmentsDuring the colonoscopycaecum, ascending colon, hepatic flexure, transverse colon, splenic flexure, descending colon, sigmoid colon, rectum
Mean number of adenomas per colonoscopyDuring the colonoscopyMean number of adenomas per colonoscopy
Advanced adenoma detection rateDuring the colonoscopyAdvanced adenoma detection rate
Sessile serrated lesion (SSL) detection rateDuring the colonoscopySessile serrated lesion (SSL) detection rate
Polyp detection rateDuring the colonoscopyPolyp detection rate
ADR for adenomas of different sizesDuring the colonoscopy\<5mm, 5-10mm, \>10mm
Caecal intubation timeDuring the colonoscopyCaecal intubation time
Withdrawal timeDuring the colonoscopyexcluding interventions
Total procedural timeDuring the colonoscopyTotal procedural time
False positive rateDuring the colonoscopydefined as computer artifacts due to colonic mucosal wall or bowel content lasting for \>2 seconds
Non-neoplastic resection rateDuring the colonoscopydefined as absence of adenoma or SSL or cancer within resected specimen

Countries

Hong Kong

Contacts

Primary ContactFelix Sia
felixsia@cuhk.edu.hk26370428
Backup ContactThomas Lam
thomaslam@cuhk.edu.hk26370428

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026